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Abstract
Purpose: The study aims to assess the tolerance of elderly patients (70 years or older) with locally advanced rectal cancers to
image-guided radiotherapy (IGRT). A retrospective review of 13 elderly patients with locally advanced rectal cancer who
underwent preoperative chemoradiation using IGRT was performed. Grade 3–4 acute toxicities, survival, and long-term
complications were compared to 17 younger patients (,70 years) with the same disease stage.
Results: Grade 3–4 hematologic toxicities occurred in 7.6% and 0% (p = 0.4) and gastrointestinal toxicities, and, in 15.2% and
5% (p = 0.5), of elderly and younger patients, respectively. Surgery was aborted in three patients, two in the elderly group
and one in the younger group. One patient in the elderly group died after surgery from cardiac arrhythmia. After a median
follow-up of 34 months, five patients had died, two in the elderly and three in the younger group. The 3-year survival was
90.9% and 87.5% (p = 0.7) for the elderly and younger group respectively. Two patients in the younger group developed
ischemic colitis and fecal incontinence. There was no statistically significant difference in acute and late toxicities as well as
survival between the two groups.
Conclusions and Clinical Relevance: Elderly patients with locally advanced rectal cancers may tolerate preoperative
chemoradiation with IGRT as well as younger patients. Further prospective studies should be performed to investigate the
potential of IGRT for possible cure in elderly patients with locally advanced rectal cancer.
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(IMRT) may potentially decrease the rates of grade 3–4 acute
toxicity and improve patient tolerance to chemoradiation by
generating a steep dose gradient [5]. Preliminary results with
IMRT are encouraging with fewer treatment breaks, less serious
toxicities, and less hospitalization in patients with rectal cancer
undergoing chemoradiation with various chemotherapy regimens
[6]. In addition to reduced toxicity, an excellent pathological
response rate and complete resection rate are reported following
chemoradiation with IMRT in patients with locally advanced
rectal cancer [7]. Thus, the potential advantage in normal tissue
sparing that is associated with IMRT may allow elderly patients to
receive curative treatment despite the presence of age-associated
co-morbidities. Image-guided radiotherapy (IGRT) is a special
technique of IMRT delivery combining the steep dose-gradient
with accurate daily imaging allowing for precise target radiation
dose delivery and further sparing of the small bowels, bladder, and
bone marrow [8,9]. Previously, we reported the feasibility of
IGRT to reduce treatment toxicity and improved pathological
response in patients with locally advanced rectal cancer undergo-

Introduction
Standard of care for locally advanced rectal cancer has been
surgery combined with chemoradiation either preoperatively or
postoperatively. Preoperative chemoradiotherapy is often preferred because of improved loco-regional control and improved
sphincter preservation [1]. The chemotherapy regimen is often
based on 5-fluorouracil (5-FU) or capecitabine with similar efficacy
when combined with radiotherapy [2]. Grade 3–4 gastrointestinal,
urologic, and hematologic toxicities are frequently the limiting
factors when chemotherapy is combined with three-dimensional
conformal radiotherapy (3D-CRT) because of excessive irradiation
of normal pelvic organs [1–3]. Given the fear of severe toxicity,
elderly patients are often excluded from randomized trials, thus
potentially depriving them from a curative treatment. Less
aggressive treatment in elderly rectal cancer patients has been
reported to increase their cancer-specific mortality even though
they may be diagnosed in less advanced stages [4]. New modalities
of radiation treatment such as intensity-modulated radiotherapy
PLOS ONE | www.plosone.org
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included if there was tumor extension to the vagina, uterus, cervix,
prostate, or bladder. The inguinal lymph nodes were treated if
there was tumor invasion of the anal canal. The planning target
volume (PTV) was generated by isotropically expanding the CTV
by a 1-cm margin. The peritoneal cavity was contoured to
represent the small bowel volume as it seems to be the most
accurate predictor of acute lower gastrointestinal toxicity to pelvic
irradiation compared to contouring single bowel loops [11]. An
integrated boost technique was used for the IGRT technique to
treat the PTV to 45 Gy at 1.8 Gy/fraction and the GTV to 50 Gy
at 2 Gy/fraction respectively. Target volume coverage was
specified to be at least 95% of the prescribed dose. Dose
constraints for normal organs at risk (OAR) for complications
were: small-bowel volume receiving 45 Gy (V45) less than 10%,
bladder: V45 less than 50%; and femoral head volumes receiving
40 Gy (V40) less than 50%. Twenty-eight patients were treated on
a helical tomotherapy unit and 2 patients on a Varian EX unit.
Daily MV CT (Tomotherapy) or fusion images (Varian EX) were
checked for treatment accuracy. All the radiation constraints were
met for tumor coverage and OAR.

Table 1. Patient characteristics.

Patient number

Younger (,70)

Older (70 or
older

Whole group

17

13

30

Sex
Male

13

9

22

Female

4

4

8

Median

62

77

67

Range

49–68

70–85

49–85

Clinical stage T3

17

13

30

5-fluorouracil

12

7

19

capecetabine

5

6

11

Median

43

34

42

Range

3–57

3–54

3–57

Age (years)

Chemotherapy

Follow-up (months)

Chemotherapy
Concurrent chemotherapy was either intravenous 5-fluorouracil
(5FU) or oral capecetabine. Capecetabine was given at an oral
dose of 825 mg/m2 twice daily, 7 days weekly, beginning on the
first day of radiotherapy and ending on the last day. 5-FU was
administered via continuous intravenous infusion with a portable
pump, at 225 mg/m2 daily during the whole course of radiotherapy. The patients were monitored during treatment with weekly
CBC, liver enzymes, electrolytes, BUN, and creatinine. Acute and
late treatment toxicity were scored according to the Radiation
Therapy Oncology Group (RTOG) scale (http://ctep.cancer.gov).

doi:10.1371/journal.pone.0071250.t001

ing chemoradiation [10]. In the current study, we further assess
the efficacy and toxicities of definitive radiotherapy delivered with
IGRT in elderly patients receiving curative treatment for locally
advanced rectal cancer.

Materials and Methods
The medical records of 30 patients undergoing neo-adjuvant
radiotherapy for locally advanced rectal cancer at the University of
Arizona Radiation Oncology department were retrospectively
reviewed. The University of Arizona institutional review board
(IRB) approved this retrospective study and waived the requirement for patient consent because of the nature of the study.
Locally advanced tumors were defined as T3, T4 tumors based on
preoperative ultrasound (US) staging. All patients had a Karnofsky
performance status of 70% or higher. All patients had a complete
history and physical examination, a digital rectal exam, a CT scan
of the chest, abdomen, and pelvis, and an endoluminal US exam.
Laboratory tests included a transaminases, alkaline phosphatase,
total bilirubin, and carcinoembryonic antigen. Prior to treatment,
each patient was simulated in the supine position with a body
vacuum bag for treatment immobilization. A computed tomography (CT) scan with and without intravenous (IV) contrast for
treatment planning was performed in the treatment position. The
abdomen and pelvis were scanned with a slice thickness of 3 mm.
Rectal and IV contrast were employed to aid in tumor localization
and in identifying grossly enlarged regional lymph node for target
volume delineation. Radiotherapy planning was performed on the
non-contrast enhanced CT scan to avoid possible interference of
contrast density with isodose distribution calculations. Diagnostic
positron emission tomography (PET)-CT scan for tumor imaging
was also incorporated with CT planning when available. Normal
organs at risk (OAR) for complications were outlined for treatment
planning (small bowels, bladder, and femoral heads). The gross
tumor volume (GTV) was outlined integrating information
obtained from the CT scan with IV and rectal contrast, the
endoscopic exam, and PET scanning when available. The clinical
target volume (CTV) included the rectum, mesorectum, presacral
space, and internal iliac nodes. The external iliac nodes were

PLOS ONE | www.plosone.org

Surgery
Patients underwent surgery 6 to 8 weeks after completion of
external beam radiation. All patients underwent a rectal endoscopy prior to surgery to assess tumor response following
chemoradiotherapy. The type of surgical procedure was determined by the surgeon based on tumor response. A sphinctersparing procedure was attempted if tumor shrinkage was deemed
sufficient to permit complete resection with negative margins.

Pathologic Evaluation
Resection margins were measured based from the inked surface
of the surgical specimen. The circumferential resection margin
(CRM) was scored as positive if the tumor was located 1 mm or
less from the inked non-peritonealized surface of the specimen. A
pathological complete response (pCR) was defined as no residual
tumor in the surgical specimen. For patients who did not achieve a
pCR, tumor size and depth of invasion were assessed on the
surgical specimen and staged according to the TNM system.

Statistical Analysis
Statistical analysis was performed with the log-rank test. A pvalue of ,0.05 is considered statistically significant. Survival data
was analyzed using Kaplan-Meier estimation.

Results
Patient Characteristics
We identified 30 patients with locally advanced adenocarcinoma of the rectum treated with preoperative IGRT chemoradiation
at the University of Arizona Radiation Oncology department from
2008 to 2012. Thirteen patients were 70 years or older (elderly)
2
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Table 2. Treatment toxicity and patient outcome.

Younger (,70)

Older (70 or older)

p-value

Mean

3.7

3.9

0.8

Range

0–19

0–14

Mean

0

1

Range

0

0–13

0

7.6

Weight loss (pounds)

Treatment breaks (days)
0.1

Grade 3–4 toxicity (%)
Hematologic
Gastrointestinal

0.4

5

15.2

0.5

Chemotherapy protocol violations (%)

17

15.2

0.1

Radiotherapy protocol violations (%)

0

7.6

0.4

Surgery aborted (%)

5

23

0.8

Long-term complications (%)

11

0

0.4

3-year survival (%)

90.9

87.5

0.7

Local recurrences (%)

7.6

6.6

0.4

Distant metastasis (%)

17.6

15.4

0.7

doi:10.1371/journal.pone.0071250.t002

elderly group had a treatment break secondary to his pseudomembranous colitis.
Among the five patients who had chemotherapy protocol
violations (dose reduction, delay or discontinuation of chemotherapy), two were in the elderly group and three in the younger
group.
Among four patients who did not undergo surgery following
chemoradiation, three were in the elderly group and one in the
younger group. One elderly patient had surgery aborted because
of liver metastases at laparotomy, another one died from cardiac
arrhythmia before the scheduled surgery, and the third one
declined surgery. The patient in the younger group declined
surgery when she was told that she would need an abdominopelvic resection because of the tumor location.
All 26 operated patients achieved a complete resection with
negative margins. Among the nine patients (30%) who achieved a
pCR, three were in the elderly group and the other six were in the
younger group.

and 17 were less than 70 years (younger), Median age at diagnosis
was 77 (range:70–85) and 62 years (range:49–68) for elderly and
younger patients respectively. There were four females in both
groups, nine males in the elderly group and 13 males in the
younger group. All patients had T3 disease on endoscopic
ultrasound. Perirectal lymph nodes were present in three patients,
two of the elderly group and one of the younger group.
Chemotherapy consisted of 5-FU in 19 patients (7 of the elderly
and 12 of the younger group), and capecitabine in 11 patients (6 of
the elderly and 5 of the younger group). Table 1 summarizes
patient characteristics.

Acute Toxicities
During radiotherapy, one patient in the elderly group developed
grade 4 diarrhea secondary to pseudomembranous colitis and
required a treatment break of 13 days. Another elderly cancer
patient mistook capecitabine for another medication and had an
overdose resulting in grade 4 diarrhea and anemia requiring
repeated blood transfusion. Her radiotherapy was discontinued
after 28 Gy. One patient in the younger group had grade 3
diarrhea. There was no hematologic toxicity in the younger group.
One patient in the younger group developed grade 3 diarrhea.
Mean weight loss was 3.7 and 3.9 pounds for elderly and
younger patients respectively. No patient in the younger group
had a radiotherapy treatment break. Only one patient in the

Treatment Outcomes
After a median follow-up of 42 months (range 3–57), the 3-year
survival was estimated to be 90.9% and 87.5% for the elderly and
younger patient respectively (p = 0.7). No patient who underwent
surgery developed a local recurrence. The local recurrence rate
was estimated to be 7.6% and 6.6% for the elderly and younger

Table 3. Treatment toxicity reported in studies using IMRT and chemotherapy for the treatment of locally advanced rectal cancer.

Study

Patient No

Grade 3–4 gastrointestinal
toxicity (%)

Grade 3–4 hematologic
toxicity (%)

Treatment breaks (%)

Arbea et al [7]

100

21

2

14

Samuelan et al [15]

31

3

3

16.2

Li et al [16]

63

9.5

1.6

11.1

Ballanoff et al [17]

8

12

0

12

doi:10.1371/journal.pone.0071250.t003
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patients respectively (p = 0.4). Corresponding numbers for distant
metastasis were 17.6% and 15.4% (p = 1). Among five patients
who developed distant metastases (liver:4, lung and liver:1), two
were in the elderly group and three were in the younger group.
One patient in the younger group developed a second lung
primary and was salvaged with surgery. The two patients who
developed long-term complications were in the younger group.
One had ischemic colitis and the other one had rectal
incontinence. Table 2 summarizes treatment outcomes and
toxicities in the two groups.

beneficial to improve elderly rectal cancer patients tolerance to
radiation and allow them to have curative resection despite the
associated co-morbidity. Indeed, in our study, all patients tolerated
chemoradiation quite well and elderly patients fared as well as
younger patients with no significant difference in treatment break
or weight loss. Acute grade 3–4 toxicity was acceptable in both
groups. Our results compared favorably with other studies using
IMRT with chemotherapy for locally advanced rectal cancer. The
reported acute grade 3–4 radiation enteritis and hematologic
toxicity range from 3% to 24% and 0 to 3% respectively. The
percentage of patients who have radiotherapy treatment break
range from 11.1% to 16.2% [7,18–20]. Table 3 summarizes acute
toxicity in patients with locally advanced rectal cancer treated with
IMRT and chemotherapy.
Despite the small number of patients, our study highlights the
possibility that elderly rectal cancer patients may tolerate
chemoradiation better with new techniques of radiotherapy that
spare the normal pelvic organs from excessive radiation. Most
often, elderly rectal cancer patients are deprived from chemotherapy or radiotherapy because of the age bias [21,22]. The
nihilistic attitude toward elderly patients results in sub-optimal
treatment and poor survival (22). Elderly rectal cancer patients
who were able to undergo surgery had a significantly better
survival compared to the ones who did not have surgery [23].
Image-guided radiotherapy may provide elderly cancer patients a
better chance for curative resection and improved survival.
The limitations of the present study include its retrospective
nature, the small number of patients, the absence of co-morbidity
information, and the relatively short median follow-up. Nevertheless, IGRT may be a new treatment modality to reduce acute
toxicity during chemoradiation for locally advanced rectal cancer
and improve tolerance to treatment in elderly cancer patients.
Further studies with a larger patient population should be
performed to investigate the potential of IGRT for curative
treatment in elderly rectal cancer patients.

Discussion
To our knowledge, this is the first study looking at the feasibility
of IGRT for elderly patients with locally advanced rectal cancers.
Despite a small number of patients, our study suggests that elderly
rectal cancer patients tolerate chemoradiation quite well andare
able to undergo surgery with excellent loco-regional control
because of a high complete resection rate. In the past, there were
concerns that elderly rectal cancer patients may not tolerate the
combined modality very well because of the expected toxicity of
treating a large volume of bowels with conventional chemoradiation technique [12,13]. Indeed, in studies that reported a high rate
of gastrointestinal toxicities and poor tolerance to the combined
modality in elderly rectal cancer patients, one-third of the patients
were treated with postoperative chemoradiation which has been
associated with a higher acute and long-term toxicity compared to
preoperative chemoradiation [13,14]. In addition, most of the
treatment breaks were secondary to radiation enteritis associated
with excessive bowel irradiation with 3D-CRT [13]. As an
illustration, death from myocardial infarction and protocol
violations requiring chemotherapy dose reduction and/or radiotherapy interruption secondary to severe toxicity have been
reported in 32% of patients with locally advanced cancer treated
with capecitabine and oxaliplatin concurrently with 3D-CRT
[15]. However, using the same chemotherapy regimen, Sola et al
reported that pelvic radiation with IMRT for locally advanced
rectal cancer was better tolerated with less interruption of the
treatment schedule [7]. Thus, bowel sparing and bone marrow
sparring through IMRTmay improve patient tolerance to
chemoradiation, allowing them to undergo surgery for complete
resection and possible cure for their rectal cancer [5,6]. Imageguided radiotherapy may further improve patient tolerance to
chemoradiation because of daily CT imaging allowing for more
accurate radiation delivery, and rapid dose fall off comparing to
conventional IMRT technique [9,16]. A simultaneous integrated
tumor boost (SIB) delivering a higher radiation dose to the gross
tumor while sparing the normal organs may also be achieved to
improve local control without excessive increase in acute toxicity
[17]. The favorable acute toxicity profile of IGRT may be

Conclusion
Image-guided radiotherapy in the setting of chemoradiation is
well tolerated in elderly patients with rectal cancer. The potential
of IGRT to help elderly rectal cancer patients achieve a curative
resection should be investigated in future clinical trials.
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